|
|||||
|
|
Beyond the dose‐limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program |
|
| Authors: | Alexander Drilon MD Anne A. Eaton MS Katja Schindler MD Mrinal M. Gounder MD David R. Spriggs MD Pamela Harris MD S. Percy Ivy MD Alexia Iasonos PhD Mario E. Lacouture MD David M. Hyman MD |
| Affiliation: | 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;2. Department of Medicine, Weill Cornell Medical College, New York, New York;3. Dermatology Department, Medical University of Vienna, Vienna, Austria;4. Cancer Therapeutics and Evaluation Program, National Cancer Institute, Bethesda, Maryland |
| Abstract: | |
| Keywords: | Cancer Therapeutics Evaluation Program (CTEP) dermatologic toxicity dose‐limiting toxicity (DLT) period phase 1 trial molecularly targeted agents |